Intercalated Treatment of Advanced Non-Small Cell Lung Cancer Patients with Grad
PUBLISHED: 2015-11-26  428 total views, 2 today

Yuejiao Zhong1, Xiaofeng Sun2, Pingping Wu2, Qin Zhou2Huayun Zhu2, Lingxiang Chen2, Jia Chen2

1Department of Internal Medicine, Jiangsu Province Cancer Hospital, Cancer Hospital Affiliated to Nanjing Medical University, 2Cancer Hospital Affiliated to Nanjing Medical University, Jiangsu Province Cancer Hospital

 

Objective:To observe the PFS (Progression FreeSurvival) could be extended inadvanced non-small cell lung cancer patients withgradual progression after failure of EGFR tyrosine kinase inhibitors therapy byintercalated treatment. Method: Collected 24 advanced NSCLC patientsafter gradual progression treated by EGFR-TKIs, from August 2009 to December2014. All of these patients were accepted intercalated treatment ofchemotherapy and EGFR-TKIs. Comparison the PFS of EGFR TKIs treatment to thegradual progression and the PFS of EGFR TKIs treatment toprogression ofintercalated treatment. Follow-up to April 30, 2015, draw the median PFSsurvival. Result: 22 patients were can be evaluated PFS. The PFS of EGFRTKIs treatment to the gradual progression was 13.3 months. The PFS of EGFR TKIstreatment to progression of intercalated treatment was 24 months (P<0.001).Conclusion: The PFS could be signally extended in NSCLC patients withgradual progression after failure of EGFR tyrosine kinase inhibitors therapy byintercalated treatment.

 

Key Words: NSCLC  gradual progression  intercalated treatment


Copyright © 1998 - 2018 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved

京公网安备 11010502031031号

Contact Us

EMAIL:office@csco.org.cn

international@csco.org.cn

Phone:86(10)67726451 (Beijing)

86(25)84547290 (Nanjing)